3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
57
Leukemia
36
Precursor Cell Lymphoblastic Leukemia-Lymphoma
27
Lymphoma
20
Congenital Abnormalities
19
Prostatic Neoplasms
18
Lymphoma, Non-Hodgkin
14
Leukemia, Erythroblastic, Acute
14
Leukemia, Myelomonocytic, Acute
13
Leukemia, Monocytic, Acute
13
Lymphoma, Large B-Cell, Diffuse
12
Lymphoma, Follicular
12
Leukemia, Megakaryoblastic, Acute
12
Myelodysplastic Syndromes
10
Lymphoma, Large-Cell, Immunoblastic
9
Leukemia, Lymphocytic, Chronic, B-Cell
7
Recurrence
5
Lymphoma, Mantle-Cell
5
Breast Neoplasms
5
Anemia, Refractory, with Excess of Blasts
5
Neoplasms
4
Leukemia, Biphenotypic, Acute
4
Burkitt Lymphoma
4
Blast Crisis
4
Ovarian Neoplasms
3
Leukemia, Myelomonocytic, Chronic
3
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
3
Leukemia, Eosinophilic, Acute
3
Leukemia, Basophilic, Acute
3
Hodgkin Disease
3
Interventions
Cytarabine
9
fludarabine
5
Imatinib Mesylate
5
thymoglobulin
3
fludarabine phosphate
3
Tacrolimus
3
Sirolimus
3
Methotrexate
3
Cyclophosphamide
3
Busulfan
3
Azacitidine
3
zosuquidar trihydrochloride
2
venetoclax
2
ponatinib
2
nilotinib
2
enasidenib
2
bosutinib
2
RO6839921
2
Mycophenolic Acid
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Etoposide
2
Behavior Therapy
2
Antilymphocyte Serum
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
spartalizumab
1
sabatolimab
1
quizartinib
1
plerixafor
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Leukemia, Myeloid
×
Mitoxantrone
×
Clear all
NCT00780104
2019-07-12
UPCC 02407
Abramson Cancer Center at Penn Medicine
Phase 1
Completed
16 enrolled